PD-1阻害は,適応性免疫抵抗を抑制することによって反応を誘導する
Paul C Tumeh1, Christina L Harview2, Jennifer H Yearley3
11] University of California Los Angeles (UCLA), Los Angeles, California 90095, USA [2] Jonsson Comprehensive Cancer Center, Los Angeles, California 90095, USA.
Nature
|November 28, 2014
まとめ
腫瘍の縁にある,PD-1/PD-L1を発現する既にあるCD8 (((+) T細胞は,抗PD-1がん治療に対する反応を予測する. この免疫抵抗メカニズムは,腫瘍の回帰のためにこれらのT細胞の必要性を強調しています.
科学分野:
- 免疫学 免疫学とは
- 腫瘍学 腫瘍学
- がん研究 がん研究
背景:
- プログラム死亡-1 (PD-1) 受容器を標的とした治療法は,様々ながんにおいて有意な臨床的反応をもたらします.
- 癌細胞はPD-1リガンド (PD-L1) のアップレギュレーションによって免疫反応を回避することができ,適応性免疫抵抗につながる.
研究 の 目的:
- 抗PD-1治療に対する反応を予測する上で,侵襲性腫瘍領域の既存のCD8 (((+)) T細胞の役割を調査する.
- PD-1/PD-L1発現とT細胞受容体 (TCR) レパートリーとの治療効果との関連を解明する.
主な方法:
- 46人の転移性メラノーマ患者の腫瘍サンプルで,抗PD-1療法 (ペムブロリズマブ) の前およびその間における定量免疫ヒストケミストリーとマルチプレックス免疫光学.
- T細胞受容体 (TCR) レパートリー分析のための次世代配列解析.
- 予測モデルの開発と検証のための多変量分析.
主要な成果:
- 治療に反応した患者は,治療前の腫瘍の侵入性領域と腫瘍内のCD8 ((+),PD-1 ((+),PD-L1 ((+) 細胞の数が高くなりました.
- PD-1とPD-L1の発現の間の密接な接近は,よりクローナルなTCRレパートリーと並行して,応答者において観察されました.
- 腫瘍内CD8 (((+) T細胞増殖は,治療中に腫瘍のサイズ減少と相関する.
- 侵襲的な限界におけるCD8発現に基づく予測モデルが開発され,検証されました.
結論:
- PD-1/PD-L1軸によって調節される,侵襲性腫瘍の限界にある,既存のCD8 (((+) T細胞は,抗PD-1阻害後の腫瘍の回帰に極めて重要です.
- この研究は,メラノーマにおける抗PD-1治療への反応を予測するバイオマーカーを特定した.
関連する概念動画
Cell-mediated Immune Responses
88.7K
Overview
88.7K
Immune Response Against Viral Pathogens
2.7K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
2.7K
Desensitization and Tachyphylaxis
3.5K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.5K
What is the Immune System?
150.9K
Overview
150.9K
B Cell Activation and Differentiation
18.9K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
18.9K
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect
249
The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
249


